ALK and non-small cell lung carcinoma: Most patients with anaplastic lymphoma kinase-positive (<i>ALK+</i>) non-small-cell lung cancer (NSCLC) could benefit from the treatment with selected tyrosine kinase inhibitors (TKIs) for a period of time, but almost inevitably progress due to drug resistance.